Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$26.99
-3.1%
$28.32
$25.17
$36.45
$4.46B0.531.78 million shs332,509 shs
Apria, Inc. stock logo
APR
Apria
$37.50
$37.45
$22.36
$40.00
$1.34BN/A682,285 shsN/A
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$15.24
-0.4%
$14.24
$10.45
$21.69
$5.40B0.63766,989 shs16,149 shs
Merus N.V. stock logo
MRUS
Merus
$68.47
-0.1%
$63.18
$33.19
$69.20
$5.16B1.19845,029 shs29,280 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
-2.11%-5.27%+4.27%-10.74%+3.84%
Apria, Inc. stock logo
APR
Apria
0.00%0.00%0.00%0.00%0.00%
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-1.15%+3.35%+12.09%+22.36%-2.70%
Merus N.V. stock logo
MRUS
Merus
+2.02%+3.39%+7.11%+24.52%+36.72%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$26.99
-3.1%
$28.32
$25.17
$36.45
$4.46B0.531.78 million shs332,509 shs
Apria, Inc. stock logo
APR
Apria
$37.50
$37.45
$22.36
$40.00
$1.34BN/A682,285 shsN/A
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$15.24
-0.4%
$14.24
$10.45
$21.69
$5.40B0.63766,989 shs16,149 shs
Merus N.V. stock logo
MRUS
Merus
$68.47
-0.1%
$63.18
$33.19
$69.20
$5.16B1.19845,029 shs29,280 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
-2.11%-5.27%+4.27%-10.74%+3.84%
Apria, Inc. stock logo
APR
Apria
0.00%0.00%0.00%0.00%0.00%
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-1.15%+3.35%+12.09%+22.36%-2.70%
Merus N.V. stock logo
MRUS
Merus
+2.02%+3.39%+7.11%+24.52%+36.72%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alkermes plc stock logo
ALKS
Alkermes
2.92
Moderate Buy$42.0055.61% Upside
Apria, Inc. stock logo
APR
Apria
0.00
N/AN/AN/A
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2.18
Hold$15.562.10% Upside
Merus N.V. stock logo
MRUS
Merus
3.08
Buy$88.7529.62% Upside

Current Analyst Ratings Breakdown

Latest APR, BLCO, MRUS, and ALKS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/9/2025
Alkermes plc stock logo
ALKS
Alkermes
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$34.00 ➝ $35.00
9/9/2025
Alkermes plc stock logo
ALKS
Alkermes
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$46.00
9/3/2025
Alkermes plc stock logo
ALKS
Alkermes
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/2/2025
Alkermes plc stock logo
ALKS
Alkermes
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$44.00
8/25/2025
Merus N.V. stock logo
MRUS
Merus
Industrial Alliance Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$90.00
8/25/2025
Merus N.V. stock logo
MRUS
Merus
Alliance Global Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$90.00
8/12/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
8/6/2025
Merus N.V. stock logo
MRUS
Merus
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/6/2025
Merus N.V. stock logo
MRUS
Merus
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$97.00 ➝ $96.00
8/1/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$12.00 ➝ $13.00
7/31/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$15.00 ➝ $16.00
(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alkermes plc stock logo
ALKS
Alkermes
$1.56B2.86$2.52 per share10.73$9.05 per share2.98
Apria, Inc. stock logo
APR
Apria
$1.15B1.17$5.27 per share7.12$1.12 per share33.48
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$4.79B1.13$1.84 per share8.29$18.57 per share0.82
Merus N.V. stock logo
MRUS
Merus
$36.13M143.33N/AN/A$9.46 per share7.24
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alkermes plc stock logo
ALKS
Alkermes
$367.07M$2.0813.0019.701.6423.15%24.86%17.14%10/23/2025 (Estimated)
Apria, Inc. stock logo
APR
Apria
$64.88MN/A0.0020.49N/A5.66%586.18%9.23%N/A
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-$317M-$0.78N/A15.871.58-5.58%2.33%1.12%10/29/2025 (Estimated)
Merus N.V. stock logo
MRUS
Merus
-$215.33M-$5.50N/AN/AN/A-685.64%-50.28%-42.00%10/30/2025 (Estimated)

Latest APR, BLCO, MRUS, and ALKS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q1 2025
Merus N.V. stock logo
MRUS
Merus
-$1.17-$2.23-$1.06-$2.23$9.77 million$8.83 million
7/30/2025Q2 2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.06$0.07+$0.01-$0.18$1.25 billion$1.28 billion
7/29/2025Q2 2025
Alkermes plc stock logo
ALKS
Alkermes
$0.42$0.52+$0.10$0.52$343.20 million$390.66 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alkermes plc stock logo
ALKS
Alkermes
N/AN/AN/AN/AN/A
Apria, Inc. stock logo
APR
Apria
N/AN/AN/AN/AN/A
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
Merus N.V. stock logo
MRUS
Merus
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alkermes plc stock logo
ALKS
Alkermes
N/A
3.23
2.85
Apria, Inc. stock logo
APR
Apria
8.58
1.09
1.06
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.76
1.55
0.98
Merus N.V. stock logo
MRUS
Merus
N/A
8.39
8.39

Institutional Ownership

CompanyInstitutional Ownership
Alkermes plc stock logo
ALKS
Alkermes
95.21%
Apria, Inc. stock logo
APR
Apria
N/A
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
11.07%
Merus N.V. stock logo
MRUS
Merus
96.14%

Insider Ownership

CompanyInsider Ownership
Alkermes plc stock logo
ALKS
Alkermes
4.40%
Apria, Inc. stock logo
APR
Apria
N/A
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.15%
Merus N.V. stock logo
MRUS
Merus
3.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alkermes plc stock logo
ALKS
Alkermes
1,800165.08 million157.82 millionOptionable
Apria, Inc. stock logo
APR
Apria
6,08035.65 millionN/ANot Optionable
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
13,500354.04 million353.46 millionOptionable
Merus N.V. stock logo
MRUS
Merus
3775.63 million72.84 millionOptionable

Recent News About These Companies

Samlyn Capital LLC Sells 288,750 Shares of Merus N.V. $MRUS
Alyeska Investment Group L.P. Lowers Stake in Merus N.V. $MRUS
Analysts Set Merus N.V. (NASDAQ:MRUS) Target Price at $88.75
Bicara Therapeutics: Promising, But Only For The Patient

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alkermes stock logo

Alkermes NASDAQ:ALKS

$26.99 -0.86 (-3.09%)
As of 10:30 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Apria stock logo

Apria NYSE:APR

Apria, Inc. provides integrated home healthcare equipment and related services in the United States. The company offers home respiratory therapies, including the supply of stationary and portable home oxygen equipment, and non-invasive ventilators; obstructive sleep apnea therapy devices comprising continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services; and negative pressure wound therapy products. It also provides a range of home medical equipment and other products, and services for patients with home care needs; and clinical and administrative support services, and related products and supplies to patients. Apria, Inc. was incorporated in 2018 and is headquartered in Indianapolis, Indiana. As of March 29, 2022, Apria, Inc. operates as a subsidiary of Byram Healthcare Centers, Inc.

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$15.24 -0.07 (-0.42%)
As of 10:29 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Merus stock logo

Merus NASDAQ:MRUS

$68.47 -0.08 (-0.12%)
As of 10:30 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.